large cell neuroendocrine carcinoma
Disease Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Therapy Indication/Tumor Type Response Type Profile Response Detail
EML4 - ALK Alectinib large cell neuroendocrine carcinoma predicted - sensitive detail...
EML4 - ALK ALK V1180L ALK G1202R Alectinib large cell neuroendocrine carcinoma predicted - resistant detail...
EML4 - ALK ALK V1180L ALK G1202R Brigatinib large cell neuroendocrine carcinoma predicted - resistant detail...
EML4 - ALK ALK V1180L ALK G1202R Lorlatinib large cell neuroendocrine carcinoma predicted - sensitive detail...
EML4 - ALK Crizotinib large cell neuroendocrine carcinoma predicted - sensitive detail...
EML4 - ALK ALK V1180L Alectinib large cell neuroendocrine carcinoma predicted - resistant detail...
EML4 - ALK ALK L1196M Brigatinib large cell neuroendocrine carcinoma no benefit detail...
EML4 - ALK ALK L1196M ALK G1202R ALK D1203N Lorlatinib large cell neuroendocrine carcinoma predicted - resistant detail...
ALK rearrange Alectinib large cell neuroendocrine carcinoma predicted - sensitive detail...
EML4 - ALK Alectinib + Zoledronic acid large cell neuroendocrine carcinoma predicted - sensitive detail...
BRAF G469R Dabrafenib + Trametinib large cell neuroendocrine carcinoma predicted - sensitive detail...
BRAF V600E Dabrafenib + Trametinib large cell neuroendocrine carcinoma predicted - sensitive detail...
EML4 - ALK Brigatinib large cell neuroendocrine carcinoma predicted - sensitive detail...
Clinical Trial Phase Therapies Title Recruitment Status Covered Countries Other Countries
NCT02936323 Phase Ib/II PEN-221 PEN-221 in Somatostatin Receptor 2 Expressing Advanced Cancers Including Neuroendocrine and Small Cell Lung Cancers Completed USA | GBR 0
NCT03901378 Phase II Carboplatin + Etoposide + Pembrolizumab Pembrolizumab Cisplatin + Etoposide + Pembrolizumab Pembrolizumab With Chemotherapy in Metastatic or Unresectable High Grade Gastroenteropancreatic or Lung Neuroendocrine Carcinoma Withdrawn USA 0
NCT04079712 Phase II Cabozantinib + Ipilimumab + Nivolumab Testing the Combination of XL184 (Cabozantinib), Nivolumab, and Ipilimumab for Poorly Differentiated Neuroendocrine Tumors Active, not recruiting USA | CAN 0
NCT04427787 Phase II Cabozantinib + Lanreotide acetate A Trial Aiming to Assess the Safety and Activity of the Combination of Cabozantinib Plus Lanreotide in GEP and NET (LOLA) Unknown status ITA 0
NCT04429087 Phase I BI 764532 A Study to Test Different Doses of BI 764532 in Patients With Small Cell Lung Cancer and Other Neuroendocrine Tumours That Are Positive for DLL3 Recruiting USA | ESP | DEU 1
NCT05599984 Phase I ABBV-706 ABBV-706 + Budigalimab ABBV-706 + Cisplatin ABBV-706 + Carboplatin Study to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab, Cisplatin, or Carboplatin in Adult Participants With Advanced Solid Tumors Active, not recruiting USA | ITA | ISR | FRA | ESP | DEU | AUS 3
NCT05652686 Phase I PT217 A Study of PT217 in Patients With Neuroendocrine Carcinomas Expressing DLL3 (the SKYBRIDGE Study) Recruiting USA 0
NCT05882058 Phase II BI 764532 DAREO-5: A Study to Test Whether Different Doses of BI 764532 Help People With Small Cell Lung Cancer or Other Neuroendocrine Cancers Recruiting USA | GBR | FRA | ESP | DEU | BGR | BEL 5
NCT06132113 Phase I BI 764532 + Cisplatin + Etoposide BI 764532 + Carboplatin + Etoposide DAREON-7: A Study to Test How Well Different Doses of BI 764532 in Addition to Chemotherapy Are Tolerated by People With Advanced Neuroendocrine Cancers Recruiting USA | SWE | NLD | FRA | ESP | DEU | BEL 1
NCT06176989 Phase II Enasidenib Enasidenib in IDH2-Mutated Malignant Sinonasal and Skull Base Tumors Recruiting USA 0
NCT06418087 Phase II Carboplatin + Durvalumab + Etoposide Durvalumab With Carboplatin and Etoposide Chemotherapy in Pulmonary Large-cell Neuroendocrine Carcinoma (LCNEC) (DUPLE) Recruiting ITA 0
NCT06736418 Phase I 225Ac-ABD147 Study of 225Ac-ABD147 to Establish Optimal Dose in Patients with SCLC and LCNEC of the Lung That Previously Received Platinum-based Chemotherapy Recruiting USA 0
NCT06788938 Phase II Tarlatamab Tarlatamab in Advanced Delta-like 3 (DLL3)-Expressing Tumors Including Neuroendocrine Neoplasms Recruiting USA 0
NCT06814496 Phase Ib/II Tarlatamab Radiation Combined With BIspecific T-Cell Engager in DLL3 Expressing Tumors (RABBIT) Recruiting USA 0
NCT06889493 Phase I Ipilimumab + Nivolumab + SVV-001 SVV-001 with Nivolumab and Ipilimumab in Patients with Poorly Differentiated Neuroendocrine Carcinomas (NEC) or Well-Differentiated High-Grade Neuroendocrine Tumors (NET) Recruiting USA 0
NCT07080242 Phase I BL-M14D1 Evaluating BL-M14D1 in Subjects With Locally Advanced or Metastatic Small Cell Lung Cancer and Neuroendocrine Tumors Recruiting USA 0